Remove getting-personal-with-vaccine-development
article thumbnail

Getting ‘Personal’ With Vaccine Development

PharmExec

Innovative and continuous remote patient monitoring, along with AI-based predictive analytics, are advancing progress toward replacing the one-size-fits-all, population-driven vaccination model.

article thumbnail

STAT+: Merck pays $250 million to license a Moderna skin-cancer vaccine candidate

STAT

Merck on Wednesday agreed to extend an ongoing collaboration with Moderna to develop a personalized vaccine for the treatment of patients with skin cancer. Moderna is getting $250 million from Merck to secure opt-in rights to the cancer vaccine candidate, called mRNA-4157.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Moderna takes aim at global expansion plans with manufacturing ramp-up

Pharmaceutical Technology

In 2020, Moderna made a net loss of $747 million while its investigational mRNA vaccines were under development. However, during the Covid-19 pandemic, the US-based biotech rose to prominence as it was one of the first companies to develop Covid-19 vaccines with its mRNA technology. billion in Covid-19 vaccine sales.

article thumbnail

Health Experts’ Predictions for the 2022 Flu Season

BuzzRx

Keep in mind that the number of flu cases and the severity of flu illness are affected by decisions made at a personal level. Influenza-associated hospitalizations can be more or less depending on whether people are wearing face masks , practicing social distancing, and vaccination rates for the flu virus.

article thumbnail

Merck gets on board with Moderna cancer vaccine in $250m deal

pharmaphorum

Shares in Moderna were ticking upwards today after Merck & Co took up an option on a personalised RNA-based cancer vaccine with a payment of $250 million. As we all know, cancer vaccines have had a rough history. — Brad Loncar (@bradloncar) October 12, 2022. — Brad Loncar (@bradloncar) October 12, 2022.

Vaccines 103
article thumbnail

Look out GSK, Pfizer and BioNTech are coming for Shingrix

pharmaphorum

GlaxoSmithKline places shingles vaccine Shingrix is among its top prospects, with peak sales potential of almost $6 billion. There’s also regulatory annd sales milestones totaling up to $200 million at the back end of the deal, and BioNTech will also get a share of gross profits from any future sales.

Vaccines 101
article thumbnail

Myths? Busted! Debunking Common Pharmacy Myths

Pharmacy Is Right For Me

So, whether it’s research and drug development, consulting, analytics, government service, or economics, pharmacists are using their skills in a multitude of ways. Pharmacy Myth 3: I’m too old to get into pharmacy. For example, some pharmacists offer flu shots and other vaccinations to their patients.